The FDA has greenlit Moleculin Biotech's plan to test its experimental cancer drug in children, marking a significant step toward potential new treatment options for pediatric patients. This means the company can now move forward with clinical trials specifically designed for younger age groups—a critical hurdle in drug development.

Editor’s Note: Pediatric cancer treatments often lag behind adult options, so regulatory approval for a new study is a big deal. If successful, this drug could offer hope for kids with limited alternatives. It’s also a signal that regulators and researchers are prioritizing younger patients, which isn’t always the case in drug development.